0001209191-18-012484.txt : 20180222 0001209191-18-012484.hdr.sgml : 20180222 20180222164622 ACCESSION NUMBER: 0001209191-18-012484 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180220 FILED AS OF DATE: 20180222 DATE AS OF CHANGE: 20180222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRYSKA DAVID W CENTRAL INDEX KEY: 0001202335 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 18633194 MAIL ADDRESS: STREET 1: 749 N MARY AVE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-20 0 0000879169 INCYTE CORP INCY 0001202335 GRYSKA DAVID W 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 Executive Vice President, CFO Common Stock 2018-02-20 4 F 0 1070 86.03 D 12922 D Common Stock 2018-02-21 4 S 0 1952 85.56 D 10970 D Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Represents weighted average sale price. Actual sale prices ranged from $85.11 - $86.28. Includes an aggregate of 10,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. /s/ David W. Gryska 2018-02-22